What You Should Know
- Kanvas Biosciences has raised $48M in Series A funding co-led by DCVC and Lions Capital LLC, bringing total funding to $78M.
- The capital will fund clinical trials for KAN-001, an immuno-oncology drug candidate designed for cancer patients who do not respond to immune checkpoint inhibitors (ICIs).
- The company utilizes a unique spatial mapping platform to visualize microbial and host cell interactions, overcoming traditional roadblocks in microbiome therapeutic development.
- Kanvas is also partnering with the Gates Foundation to develop the first fully synthetic microbiome replacement for maternal environmental enteric dysfunction.
- Recent milestones include the opening of a GMP manufacturing suite and the development of the Kanvas Spectral Lightsheet, a high-resolution microscope for building a microbiome atlas.
Despite the promise of immunotherapy, only 10% of solid organ cancer patients achieve complete responses to immune checkpoint inhibitors (ICIs). Kanvas Biosciences, a full-stack spatial biology company, is working to bridge this “intelligence gap” by treating the microbiome as a distinct, modifiable organ. With a fresh $48M in Series A funding, the company is now prepared to transition its spatial imaging and manufacturing platform into the clinical arena, targeting the complex host-microbiome interactions that dictate treatment success.
The funding will primarily support clinical trials for KAN-001, a live biotherapeutic product (LBP). While fecal microbiota transplants (FMT) have shown the ability to convert ICI non-responders into responders, they are hindered by scalability and safety risks. KAN-001 is designed to provide a standardized, manufactured alternative that restores microbiome health and enhances the efficacy of existing cancer therapies.
Beyond Sequencing: The Power of Spatial Intelligence
Traditional microbiome research has relied heavily on metagenomics sequencing, which identifies what is in the gut but often misses where those microbes are located and how they function. Kanvas’ platform provides a “visual intelligence layer” that outperforms these gold-standard methods, particularly in low biomass settings.
Key technological differentiators include:
- Spatial Mapping: The ability to visualize LBP engraftment and activity in real-time within host tissues.
- Kanvas Spectral Lightsheet: A proprietary microscope that generates unprecedented volumes of spatial data to train the company’s AI platform.
- Synthetic Microbiome Consortia: The capability to manufacture complex microbial groups containing hundreds of members designed to restore gastrointestinal health.
Expanding Global and Clinical Footprints
Kanvas’ mission extends beyond oncology into global health and specialized maternal care. Supported by the Gates Foundation, the company is developing a synthetic microbiome product to address maternal environmental enteric dysfunction, a condition linked to neonatal health risks and undernutrition. Additionally, preparations are underway for a Phase 1 trial of KAN-004, a candidate targeting ICI-induced colitis to help patients remain on life-saving therapy longer.
The addition of Stephen Quake to the Board of Directors further strengthens the company’s technical and scientific leadership as it operationalizes its new GMP manufacturing suite in Princeton, NJ.
